NCT05803135 - Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis | Biotech Hunter

Enrollment

138

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

December 30, 2025

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Iguratimod combined with Tofacitinib;

Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)